

This is a repository copy of *German EstSmoke : Estimating adult smoking-related costs and consequences of smoking cessation for Germany*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/119626/>

Version: Accepted Version

Article:

Sonntag, Diana, Gilbody, Simon orcid.org/0000-0002-8236-6983, Volker, Winkler et al. (1 more author) (2018) *German EstSmoke : Estimating adult smoking-related costs and consequences of smoking cessation for Germany*. *Addiction*. pp. 125-136. ISSN 1360-0443

<https://doi.org/10.1111/add.13956>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Tables and Figures

German EstSmoke: Estimating adult smoking-related costs and consequences of smoking cessation for Germany

Diana Sonntag^{1,2}, PhD, Simon Gilbody³, DPhil/PhD, Winkler Volker⁴, PD, PhD,
Shehzad Ali², PhD, MPH, MBBS

¹ Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim of the Heidelberg University, Germany

² Department of Health Sciences, University of York, York, UK

³ Department of Health Sciences and HYM, University of York, York, UK

⁴ Institute of Public Health, Heidelberg University Hospital, Germany

Table 1: Prevalence of never, current and ex-smokers by age group and sex

Cigarette smoking status	Age groups	Men (%)	Women (%)
Never smoker	18-24	50	54
	25-34	34	40
	35-44	35	44
	45-54	30	40
	55-64	31	51
	65-69	34	61
	70 and over	34	73
	ALL	35	52
Current smoker	18-24	38	34
	25-34	48	38
	35-44	43	34
	45-54	40	34
	55-64	27	24
	65-69	17	15
	70 and over	12	7
	ALL	34	26
Ex-smoker	18-24	11	12
	25-34	18	22
	35-44	22	22
	45-54	30	26
	55-64	24	25
	65-69	49	24
	70 and over	54	20
	ALL	31	22

Table 2: Parameter values for Markov model and distribution of Monte Carlo Simulation

Model parameter	Parameter value	Distribution used Monte Carlo Simulation	Source
I. Epidemiology			
<i>Transition Probabilities</i>			
<i>First-ever</i> MI stroke lung cancer COPD	Appendix 2	(None)	calculated based on i) MONICA/KORA MI Registry (25), ii) Erlangen Stroke Project (ESPrO) (26), iii) the Association of Population-based Cancer Registries in Germany (GEKID) Atlas (27), and iv) the European Community Respiratory Health Survey (ECRHS) (28).
<i>Recurrent</i> MI stroke	men women men women	0.19 0.21 0.14 0.06	(None) (None)
<i>Fatal</i> MI stroke lung cancer COPD death due to other diseases	Appendix 4	(None)	calculated based on Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR) (35). calculated based on the Ischaemic Stroke Patients (SCALA) study (36). calculated based on (25), (26), (27), and (34).
<i>Odds ratios or relative risks of</i>			
<i>First ever MI in</i> smokers men	3.33 [Ages: 35-55]	Log-Normal (1.2; 0.34)*	Yusuf et al.

	women	2.52 [Ages: >55] 4.49 [Ages: 35-64] 2.14 [Ages: >65]	Log-Normal (0.92; 0.31)* Log-Normal (1.5; 0.72)* Log-Normal (0.76; 0.90)*	2004
	ex-smokers#	2.00 [Ages: 35-39] 1.63 [Ages: 40-49] 1.67 [Ages: 50-59] 1.51 [Ages: 60+]	Log-Normal (0.69; 0.67)* Log-Normal (0.49; 0.39)* Log-Normal (0.51; 0.38)* Log-Normal (0.41; 0.40)*	Yusuf et al. 2004
	time since quit	1.88 (>1-3 years) 1.65 (>3-10 years) 1.61 (>10-15 years) 1.44 (>15 years)	Log-Normal (0.63; 0.35)* Log-Normal (0.50; 0.36)* Log-Normal (0.48; 0.29)* Log-Normal (0.36; 0.24)*	Yusuf et al. 2004
<i>First ever stroke in</i>	smokers			
	men	2.01	Log-Normal (0.70; 0.66)*	Chiuve et al.
	women	2.59	Log-Normal (0.95; 0.36)*	2008
	ex-smokers#	1.12	Log-Normal (0.11; 0.22)*	Chiuve et al. 2008
	time since quit	0.73 (<2 years) 0.59 (2-4years) 0.59 (>5 years)	Log-Normal*	Kawachi et al. 1993
<i>Lung cancer in</i>	smokers			
	men	23.6	Log-Normal (3.16; 0.28)*	Pesch et al.
	women	7.8	Log-Normal (2.05; 0.27)*	2011
	ex-smokers#			
	men	7.5	Log-Normal (2.01; 0.29)*	Pesch et al.
	women	2.8	Log-Normal (1.03; 0.31)*	2011
	time since quit	18.3 (2-5 years, men) 10.8 (6-10 years, men) 2.9 (26-35 years, men) 6.7 (2-5 years, women)	Log-Normal (2.91; 0.35)* Log-Normal (2,38; 0.35)* Log-Normal (1.06; 0.37)* Log-Normal (1,90; 0.55)*	Pesch et al. 2011

<i>COPD in</i>	smokers	4.00 (6-10 years, women)	Log-Normal (1.39; 0.58)*	Cerveri et al. 2001
		1.00 (26-35 years, women)	Log-Normal (0.00; 0.96)*	
<i>Other diseases</i>	men	6.32	Log-Normal (1.84; 0.80)*	Cerveri et al. 2001
		3.06	Log-Normal (1.12; 0.71)*	
	ex-smokers#	1.38	Log-Normal (0.32; 0.97)*	Cerveri et al. 2001
		1.08	Log-Normal (0.08; 0.92)*	
	smokers	2.25	Log-Normal (0.81; 0.15)*	calculated based on Mons 2011
	ex-smokers#	1.55	Log-Normal (0.44; 0.16)*	Kenfield et al. 2008
II. Costs				
<i>MI</i>				
Initial treatment acute MI	€15.386	Gamma distribution	Brueggenjuergen et al. 2005, 2011	
MI state (1 year)	€8.560		Annemans et al. 2006	
After MI state (2 year and after)	€2.323			
Cost of death from MI (fatal MI)	€3.446			
<i>Stroke</i>				
Acute stroke management	€6.048	Gamma distribution	Brueggenjuergen et al. 2005	
Post-stroke (1 year)	€14.996		Annemans et al. 2006	
Post-stroke (year 2 and after)	€6.486			
Fatal stroke	€2.270			
<i>Lung cancer</i>				
Annual cost	€621	Gamma distribution	Schwarzkopf et al. 2015	
Lung cancer (Initial treatment)	€11.987		calculated based on US EPA 2006	
Lung cancer (terminal care)	€13.860			
<i>COPD</i>				
Annual cost	€2.495	Gamma distribution	Menn et al. 2012	
Cost of death from COPD	€2.040		Nowak et al. 2004	

<i>Death from other causes</i>	€4.801	Gamma distribution	calculated based on Doesler et al. 2011
III. Discount rate	0.035	(None)	

* Log-Normal (ln mean, ln SE), SE Standard Error, # overall risk of ex-smokers compared to never smokers

Table 3: Lifetime costs of health care resource use due to MI, stroke, lung cancer, COPD and economic consequences of implementing WHO FCTC policies (2015)

Policy/Scenario	Discounted (yes/no)	Men	Women
I. Baseline scenario - current German tobacco policies			
Never smoker	<i>Before discounting</i>	Lifetime cost of health care use per capita €18,471	€17,881
	<i>After discounting (at 3.5%)</i>	€4,709 (1,931-10,192)	€4,092 (1,249-10,113)
Smoker	<i>Before discounting</i>	€26,816	€24,762
	<i>After discounting (at 3.5%)</i>	€8,669 (3,455-19,229)	€7,086 (2,115-18,216)
Ex-smoker	<i>Before discounting</i>	€20,135	€21,234
	<i>After discounting (at 3.5%)</i>	€5,605 (2,183-30,122)	€5,185 (1,263-35,060)
Excess cost of smoking	<i>After discounting (at 3.5%)</i>	Cost difference on population level (smokers vs. never smokers) €41.6bn	
II. Scenario - Implementing WHO FCTC policies			
Strong health warnings	<i>After discounting (at 3.5%)</i>	Cost-difference on population level (smokers vs. ex-smokers) €1.7bn	
Comprehensive marketing bans	<i>After discounting (at 3.5%)</i>	€2.2bn	
Cessation treatment policies	<i>After discounting (at 3.5%)</i>	€18.9bn	

Projected lifetime costs of health care resource use, 2015, mean=deterministic, range=2.5 and 97.5 sensitivity bounds (Monte Carlo Simulation), 10,000 runs, bn=billion

Figure 1: Markov structure for four clinical pathways related to smoking and quitting smoking




Figure 2: Distribution of cumulative health care costs in smokers and ex-smokers over lifetime




Figure 3: Predicted survival of smokers and ex-smokers

